EMEA-001178-PIP01-11-M06
Key facts
Invented name |
Stivarga
|
Active substance |
regorafenib
|
Therapeutic area |
Oncology
|
Decision number |
P/0495/2021
|
PIP number |
EMEA-001178-PIP01-11-M06
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of all conditions contained in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Bayer AG
E-mail: pediatrics.medical-affairs-europe@bayer.com |
Decision type |
PM: decision on the application for modification of an agreed PIP
|